Transcription of 薬剤耐性（AMR）に関する背景、国際社会の動向 及び我が国 …
1 AMR 27 12 24 1 (AMR) AMR AMR WHO AMR 2 G7 AMR G7 G7 AMR Sch berle TF , Hack IM, Trends Microbiol. 2014; 22: 165-7. ICU 232000 10 Van BoeckelTP et al., Lancet Infect Dis 2014; 14: 742-50. 05101520253035 JapanNetherlandsEstoniaLatviaHungaryAust riaSwedenSloveniaGermanyLithuaniaDenmark NorwayCzech RepublicBulgariaFinlandPolandSlovakiaUni ted KingdomSpain (b)CroatiaIceland (a)MaltaPortugalIrelandItalyLuxembourgCy prus (a)FranceBelgiumRomania (a)GreeceTetracyclines (J01A)Beta-lactams,penicillins(J01C)Othe r betalactam antibacterials (J01D)Sulfonamides and trimethoprim(J01E)Macrolides, Lincosamides and streptogramins(J01F)Quinolones (J01M)Other antibacterials(J01X)Sum(J01B, J01G,andJ01R)* EU 2012 ECDC AMR Surveillance report 2012, Murakiet al.
2 , Infection. 2013; 41:415-23. 4 AUD Antimicrobial Use Density; /1000 / (AMR) 2013 2050 Antimicrobial Resistance: Tackling a crisis for health and wealth of nations, the O Neill Commission, UK, December 2014 2013 AMR 70 2050 1000 70 (Antimicrobial Resistance in G7 Countries and Beyond, G7 OECD report, Sept. 2015) G7 AMR 3 2015 G WHO 2015 2015 2015 WHO 2015 AMR
3 6 2 : WHO G7 WHO WHO AMR (2015) 7G7 AMR Antimicrobial Resistance in G7 Countries and Beyond. OECD 20158 TATFAR Transatlantic Taskforce on Antimicrobial Resistance 10 11 12 1 2 3 4 5 6 7 8 9 10/8-9 5/26-27 /11-12 3 2 1 AMR AMR 9 10 AMR AMR 11 30 12 8 12
4 17 12 24 AMR (JANIS) JANIS JVARM (GenEpid-J) 17 17 Infection Control Team: ICT) 18 24 27 (AMED) 11 WHO AMR
